Tower View Wealth Management’s AstraZeneca AZN Stock Holding History

Tower View Wealth Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-250	Closed	-$33K	–	165
2022 Q1	$33K	Hold	250	–	–	0.02%	113
2021 Q4	$29K	Hold	250	–	–	0.01%	117
2021 Q3	$30K	Buy	+250	New	+$29.1K	0.02%	119
2021 Q2	–	Sell	-10	Closed	-$1K	–	170
2021 Q1	$1K	Sell	10 -15	-60%	-$1.51K	﹤0.01%	179
2020 Q4	$2K	Buy	+25	New	+$2.65K	﹤0.01%	165
2018 Q1	–	Sell	-375	Closed	-$26K	–	137
2017 Q4	$26K	Buy	+375	New	+$25.3K	0.02%	110

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Tower View Wealth Management's AZN Position: Q2 2022 in Review

Tower View Wealth Management sold out of AstraZeneca (AZN) in Q2 2022, closing a stake of 250 shares — an estimated $33K sold.

Tower View Wealth Management first reported a position in AZN in Q4 2017 and held it in 6 quarters. The position peaked at $33K in Q1 2022. 1,015 funds tracked by Wall St. Rank hold AZN as of Q2 2022.

Tower View Wealth Management reported no remaining AstraZeneca position as of Q2 2022 after selling out during the quarter.
Tower View Wealth Management sold 250 AstraZeneca shares in Q2 2022, an estimated $33K.
Tower View Wealth Management first reported a position in AstraZeneca in Q4 2017 and held it in 6 quarters.
Tower View Wealth Management's AstraZeneca position peaked at $33K in Q1 2022.
1,015 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2022.

Based on Tower View Wealth Management's 13F filing for Q2 2022, filed 8 Aug 2022.